Opposition to inclusion of the Combating Xylazine Act (H.R. 1839/S. 993) in the SUPPORT Act reauthorization (H.R. 4531).
Opposing passage of the HALT Fentanyl Act (H.R. 467/S. 1141); Supporting passage of the TEST Act (S. 1950); Supporting eliminating the drug felony ban for SNAP recipients via the RESTORE Act (H.R. 3479/S. 1753).
Requesting funding and report language for Syringe Services Programs (SSPs) in the Infectious Diseases and the Opioid Epidemic program at the Centers for Disease Control and Prevention (CDC) in the Labor, Health and Human Services, Education, and Related Agencies (LHHS) appropriations bill.
Duration: January 1, 2008
to
present
General Issues: Health Issues , Law Enforcement/Crime/Criminal Justice , Budget/Appropriations , District of Columbia , Agriculture , Unemployment , Education , Foreign Relations , Alcohol & Drug Abuse , Civil Rights/Civil Liberties
Spending: about $7,041,181 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, Substance Abuse & Mental Health Services Administration (SAMHSA), Office of Natl Drug Control Policy (NDCP), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 16.
Original Filing: 301550273.xml
Lobbying Issues
Opposition to inclusion of the Combating Xylazine Act (H.R. 1839/S. 993) in the SUPPORT Act reauthorization (H.R. 4531).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Opposing passage of the HALT Fentanyl Act (H.R. 467/S. 1141); Supporting passage of the TEST Act (S. 1950); Supporting eliminating the drug felony ban for SNAP recipients via the RESTORE Act (H.R. 3479/S. 1753).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Requesting funding and report language for Syringe Services Programs (SSPs) in the Infectious Diseases and the Opioid Epidemic program at the Centers for Disease Control and Prevention (CDC) in the Labor, Health and Human Services, Education, and Related Agencies (LHHS) appropriations bill.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2023
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 9.
Original Filing: 301522941.xml
Lobbying Issues
Opposition to inclusion of the Combating Xylazine Act (H.R. 1839/S. 993) in the SUPPORT Act reauthorization (H.R. 4531).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Opposing passage of the HALT Fentanyl Act (H.R. 467/S. 1141); Supporting passage of the TEST Act (S. 1950); Supporting eliminating the drug felony ban for SNAP recipients
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Requesting $150 million in funding and report language for Syringe Services Programs (SSPs) in the Infectious Diseases and the Opioid Epidemic program at the Centers for Disease Control and Prevention (CDC) in the FY 2024 Labor, Health and Human Services, Education, and Related Agencies (LHHS) appropriations bill.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2023
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 13, 2023.
Original Filing: 301500471.xml
Lobbying Issues
Opposing inclusion of the Combating Xylazine Act (H.R. 1839/S. 993) in the SUPPORT Act reauthorization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Opposing passage of the HALT Fentanyl Act (H.R. 467/S. 1141); Supported the Drug Policy Reform Act (H.R. 4020); Supporting reintroduction of the Cannabis Administration and Opportunity Act (CAOA) (S.4591)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Requesting $150 million in funding and report language for Syringe Services Programs (SSPs) in the Infectious Diseases and the Opioid Epidemic program at the Centers for Disease Control and Prevention (CDC) in the FY 2024 Labor, Health and Human Services, Education, and Related Agencies (LHHS) appropriations bill.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2023
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 19, 2023.
Original Filing: 301483028.xml
Lobbying Issues
Opposing inclusion of the Combating Xylazine Act (H.R. 1839/S. 993) in the SUPPORT Act reauthorization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Opposing passage of the HALT Fentanyl Act (H.R. 467/S. 1141); Supported the Drug Policy Reform Act (H.R. 4020); Supporting reintroduction of the Cannabis Administration and Opportunity Act (CAOA) (S.4591)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Requesting $150 million in funding and report language for Syringe Services Programs (SSPs) in the Infectious Diseases and the Opioid Epidemic program at the Centers for Disease Control and Prevention (CDC) in the FY 2024 Labor, Health and Human Services, Education, and Related Agencies (LHHS) appropriations bill.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2023
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 19, 2023.
Original Filing: 301457544.xml
Lobbying Issues
Supported the introduction of the Reentry Act (H.R. 2400) in the House.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Opposed passage of the HALT Fentanyl Act (H.R. 467); Supported the Drug Policy Reform Act (H.R. 4020)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Requesting $150 million in funding and report language for Syringe Services Programs (SSPs) in the Infectious Diseases and the Opioid Epidemic program at the Centers for Disease Control and Prevention (CDC) in the FY 2024 Labor, Health and Human Services, Education, and Related Agencies (LHHS) appropriations bill.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2022
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301435214.xml
Lobbying Issues
Lobbied for appropriations funding for syringe service providers and to lift the federal ban on syringes. Supported passage of MAT Act (S.445/H.R. 1384) which expands access to medication for people who use drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supported federal marijuana reform, including the expungement and resentencing of cannabis convictions. Introduced and lobbied on behalf of the Drug Policy Reform Act (HR 4020).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Lobbied for $150 million in appropriations for syringe service programs and other harm reduction tools/services. Lobbied for the MEAL Act to lift the ban on people with drug convictions receiving SNAP/TANF benefits.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2022
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 17, 2022.
Original Filing: 301406391.xml
Lobbying Issues
Lobbied for $150 million appropriations funding for syringe service providers and to lift the federal ban on syringes. Supported passage of MAT Act (S.445/H.R. 1384) which expands access to medication for people who use drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supported federal marijuana reform, including the expungement and resentencing of cannabis convictions, lobbying on behalf of the MORE Act (HR 3617). Introduced and lobbied on behalf of the Drug Policy Reform Act (HR 4020).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Lobbied for $150 million in appropriations for syringe service programs and other harm reduction tools/services.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2022
DRUG POLICY ALLIANCE amended a lobbying report for in-house lobbying in Q32022 on Oct. 17, 2022
Original Filing: 301406394.xml
Lobbying Issues
Lobbied for $150 million appropriations funding for syringe service providers and to lift the federal ban on syringes. Supported passage of MAT Act (S.445/H.R. 1384) which expands access to medication for people who use drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supported federal marijuana reform, including the expungement and resentencing of cannabis convictions, lobbying on behalf of the MORE Act (HR 3617). Introduced and lobbied on behalf of the Drug Policy Reform Act (HR 4020).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Lobbied for $150 million in appropriations for syringe service programs and other harm reduction tools/services. Lobbied for the MEAL Act to lift the ban on people with drug convictions receiving SNAP/TANF benefits.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2022
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 18, 2022.
Original Filing: 301382843.xml
Lobbying Issues
Lobbied for $150 million appropriations funding for syringe service providers and to lift the federal ban on syringes. Supported passage of MAT Act (S.445/H.R. 1384) which expands access to medication for people who use drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supported federal marijuana reform, including the expungement and resentencing of cannabis convictions, lobbying on behalf of the MORE Act (HR 3617). Introduced and lobbied on behalf of the Drug Policy Reform Act (HR 4020).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Lobbied for $150 million in appropriations for syringe service programs and other harm reduction tools/services.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2022
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 19, 2022.
Original Filing: 301362065.xml
Lobbying Issues
Lobbied for $69.5 million appropriations funding for syringe service providers and to lift the federal ban on syringes. Lobbying to pass a fentanyl harm reduction bill called the STOP Fentanyl Act (HR 2366/S 1457) which emphasizes expanding access to health services for people who use drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supported federal marijuana reform, including the expungement and resentencing of cannabis convictions, lobbying on behalf of the MORE Act (HR 3617). Introduced and lobbied on behalf of the Drug Policy Reform Act (HR 4020).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Lobbied for $69.5 million in appropriations for syringe service programs and other harm reduction tools/services.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2021
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 18, 2022.
Original Filing: 301326228.xml
Lobbying Issues
Lobbied for $69.5 million appropriations funding for syringe service providers and to lift the federal ban on syringes. Lobbying to pass a fentanyl harm reduction bill called the STOP Fentanyl Act (HR 2366/S 1457) which emphasizes expanding access to health services for people who use drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supported federal marijuana reform, including the expungement and resentencing of cannabis convictions, lobbying on behalf of the MORE Act (HR 3617). Introduced and lobbied on behalf of the Drug Policy Reform Act (HR 4020).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Lobbied for $69.5 million in appropriations for syringe service programs and other harm reduction tools/services.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2021
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 19, 2021.
Original Filing: 301306207.xml
Lobbying Issues
Lobbied for $120 million appropriations funding for syringe service providers and to lift the federal ban on syringes. Lobbying to pass a fentanyl harm reduction bill called the STOP Fentanyl Act (HR 2366/S 1457) which emphasizes expanding access to health services for people who use drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supported federal marijuana reform, including the expungement and resentencing of cannabis convictions, lobbying on behalf of the MORE Act (HR 3617). Introduced and lobbied on behalf of the Drug Policy Reform Act (HR 4020).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Lobbied for $120 million in appropriations for syringe service programs and other harm reduction tools/services.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2021
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 19, 2021.
Original Filing: 301281170.xml
Lobbying Issues
Lobbied for $120 million appropriations funding for syringe service providers and to lift the federal ban on syringes. Lobbying to pass a fentanyl harm reduction bill called the STOP Fentanyl Act (HR 2366/S 1457) which emphasizes expanding access to health services for people who use drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Lobbied the Senate to make improvements to the Justice in Policing Act (HR 1280), a federal policing bill. Lobbied on behalf of the FAIR Act(HR 2857) to end civil asset forfeiture. Supported federal marijuana reform, including the expungement and resentencing of cannabis convictions, lobbying on behalf of the MORE Act (HR 3617). Introduced and lobbied on behalf of the Drug Policy Reform Act (HR 4020).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Lobbied for $120 million in appropriations for syringe service programs and other harm reduction tools/services.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2021
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 11, 2021.
Original Filing: 301251642.xml
Lobbying Issues
Lobbied for $120 million appropriations funding for syringe service providers and to lift the federal ban on syringes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Lobbied to improving Justice in Policing Act, a federal policing bill. Supported sentencing reform bills. Supported federal marijuana reform, including the expungement and resentencing of cannabis convictions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Lobbied for $120 million in appropriations for syringe service programs and other harm reduction tools/services.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2020
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 19, 2021.
Original Filing: 301235017.xml
Lobbying Issues
Drug overdose prevention, expanding access to drug treatment and harm reduction services. HR 2482/S 2074, the Medication Assisted Treatment Act; HR 2569/S 1365, Comprehensive Addiction Resources Emergency Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Sentencing and criminal justice reform, fentanyl sentencing legislation, restoration of Pell Grants for incarcerated students and removal of barriers to financial aid for individuals with criminal convictions, marijuana reform. S 1622, the Stopping Overdoses of Fentanyl Analogues Act; S. 2701, Federal Initiative to Guarantee Health by Targeting Fentanyl Act; HR 3884, Marijuana Opportunity Reinvestment and Expungement Act. Supported efforts to release vulnerable individuals from incarcerated settings.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Advocated for funding harm reduction services in the Congressional budget in light of COVID-19 and high overdose rates.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2020
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 15, 2020.
Original Filing: 301210897.xml
Lobbying Issues
Drug overdose prevention, expanding access to drug treatment and harm reduction services. HR 2482/S 2074, the Medication Assisted Treatment Act; HR 2569/S 1365, Comprehensive Addiction Resources Emergency Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Sentencing and criminal justice reform, fentanyl sentencing legislation, restoration of Pell Grants for incarcerated students and removal of barriers to financial aid for individuals with criminal convictions, marijuana reform. S 1622, the Stopping Overdoses of Fentanyl Analogues Act; S. 2701, Federal Initiative to Guarantee Health by Targeting Fentanyl Act; HR 3884, Marijuana Opportunity Reinvestment and Expungement Act. Supported efforts to release vulnerable individuals from incarcerated settings.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Advocated for funding harm reduction services in the Congressional budget in light of COVID-19 and high overdose rates.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2020
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 17, 2020.
Original Filing: 301191095.xml
Lobbying Issues
Drug overdose prevention, expanding access to drug treatment and harm reduction services. HR 2482/S 2074, the Medication Assisted Treatment Act; HR 2569/S 1365, Comprehensive Addiction Resources Emergency Act. Supported efforts to release vulnerable individuals from incarcerated settings.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Sentencing and criminal justice reform, fentanyl sentencing legislation, restoration of Pell Grants for incarcerated students and removal of barriers to financial aid for individuals with criminal convictions, marijuana reform. S 1622, the Stopping Overdoses of Fentanyl Analogues Act; S. 2701, Federal Initiative to Guarantee Health by Targeting Fentanyl Act; HR 3884, Marijuana Opportunity Reinvestment and Expungement Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Funding for medication assisted treatment in jails and prisons; removal of a congressional rider barring Washington DC from taxing and regulating marijuana.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2020
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 15, 2020.
Original Filing: 301167630.xml
Lobbying Issues
Drug overdose prevention, expanding access to drug treatment and harm reduction services. HR 2482/S 2074, the Medication Assisted Treatment Act; HR 2569/S 1365, Comprehensive Addiction Resources Emergency Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Sentencing and criminal justice reform, fentanyl sentencing legislation, restoration of Pell Grants for incarcerated students and removal of barriers to financial aid for individuals with criminal convictions, marijuana reform. S 1622, the Stopping Overdoses of Fentanyl Analogues Act; S. 2701, Federal Initiative to Guarantee Health by Targeting Fentanyl Act; HR 3884, Marijuana Opportunity Reinvestment and Expungement Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Funding for medication assisted treatment in jails and prisons; removal of a congressional rider barring Washington DC from taxing and regulating marijuana.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2019
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301129245.xml
Lobbying Issues
Drug overdose prevention, expanding access to drug treatment and harm reduction services. HR 2482/S 2074, the Medication Assisted Treatment Act; HR 2569/S 1365, Comprehensive Addiction Resources Emergency Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Sentencing and criminal justice reform, fentanyl sentencing legislation, restoration of Pell Grants for incarcerated students and removal of barriers to financial aid for individuals with criminal convictions, marijuana reform. S 1622, the Stopping Overdoses of Fentanyl Analogues Act; S. 2701, Federal Initiative to Guarantee Health by Targeting Fentanyl Act; HR 3884, Marijuana Opportunity Reinvestment and Expungement Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Funding for medication assisted treatment in jails and prisons; removal of a congressional rider barring Washington DC from taxing and regulating marijuana.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2019
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 21, 2019.
Original Filing: 301074977.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
overdose, drug policy and criminal justice funding
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2019
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 22, 2019.
Original Filing: 301056107.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
overdose, drug policy and criminal justice funding
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2019
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 18, 2019.
Original Filing: 301028290.xml
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
overdose, drug policy and criminal justice funding
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2018
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 17, 2019.
Original Filing: 301006821.xml
Lobbying Issues
HR 2851, SITSA Act, issues related to synthetic drugs.
Issues related to drug overdose.
Issues related to collateral consequences of a drug conviction.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 1689, Marijuana Justice Act
S.3032, Strengthening the Tenth Amendment Through Entrusting States Act
Issues related to ending federal marijuana prohibition
S.1917, Sentencing Reform and Corrections Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana-related policy in federal appropriations.
Issues related to treatment provided in criminal justice settings and related policy in federal appropriations.
Issues related to funding for harm reduction and treatment in federal appropriations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2018
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 22, 2018.
Original Filing: 300994685.xml
Lobbying Issues
HR 2851, SITSA Act, issues related to synthetic drugs.
Issues related to drug overdose.
Issues related to collateral consequences of a drug conviction.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 1689, Marijuana Justice Act
S.3032, Strengthening the Tenth Amendment Through Entrusting States Act
Issues related to ending federal marijuana prohibition
S.1917, Sentencing Reform and Corrections Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana-related policy in federal appropriations.
Issues related to treatment provided in criminal justice settings and related policy in federal appropriations.
Issues related to funding for harm reduction and treatment in federal appropriations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2018
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 23, 2018.
Original Filing: 300979003.xml
Lobbying Issues
HR 2851, SITSA Act, issues related to synthetic drugs.
Issues related to drug overdose.
Issues related to collateral consequences of a drug conviction.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 1689, Marijuana Justice Act
S.3032, Strengthening the Tenth Amendment Through Entrusting States Act
Issues related to ending federal marijuana prohibition
S.1917, Sentencing Reform and Corrections Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana-related policy in federal appropriations.
Issues related to treatment provided in criminal justice settings and related policy in federal appropriations.
Issues related to funding for harm reduction and treatment in federal appropriations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2018
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 20, 2018.
Original Filing: 300955574.xml
Lobbying Issues
S. 1764, CARERS Act, issues related to medical marijuana and ending federal marijuana prohibition.
HR 2851, SITSA Act, issues related to synthetic drugs.
Issues related to drug overdose.
Issues related to collateral consequences of a drug conviction.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 1689, Marijuana Justice Act, issues related to ending federal marijuana prohibition.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana-related policy in federal appropriations.
Issues related to treatment provided in criminal justice settings and related policy in federal appropriations.
Issues related to funding for harm reduction and treatment in federal appropriations.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2017
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 20, 2018.
Original Filing: 300931761.xml
Lobbying Issues
S. 1764, CARERS Act, issues related to medical marijuana.
HR 2851, SITSA Act, issues related to synthetic drugs.
Issues related to overdose.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S 1689, Marijuana Justice Act, sssues related to ending federal marijuana prohibition.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana spending amendments.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2017
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Nov. 1, 2017.
Original Filing: 300918541.xml
Lobbying Issues
S. 1764, CARERS Act, issues related to medical marijuana.
Issues related to synthetic drugs.
Issues related to overdose.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Sentencing Reform and Corrections Act, issues relating to drug sentencing.
FAIR Act, issues relating to civil asset forfeiture.
S 1689, Marijuana Justice Act, sssues related to ending federal marijuana prohibition.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana spending amendments.
Issues related to LEAD (DOJ) funding.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2017
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Nov. 1, 2017.
Original Filing: 300918539.xml
Lobbying Issues
S. 1764, CARERS Act, issues related to medical marijuana.
Issues related to synthetic drugs.
Issues related to overdose.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Sentencing Reform and Corrections Act, issues relating to drug sentencing.
FAIR Act, issues relating to civil asset forfeiture.
S 1689, Marijuana Justice Act, sssues related to ending federal marijuana prohibition.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
4th Quarter, 2016
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Nov. 1, 2017.
Original Filing: 300918542.xml
Lobbying Issues
Opioid Overdose Reduction Act of 2014, issues related to overdose prevention.
Overdose Prevention Act, issues related to overdose prevention.
S. 524, Comprehensive Addiction Recovery Act
S. 683, CARERS Act, issues related to medical marijuana.
H.R. 3537, the Synthetic Drug Control Act of 2015, issues related to DEA authority.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Sentencing Reform and Corrections Act, issues relating to drug sentencing.
FAIR Act, issues relating to civil asset forfeiture.
Issues related to ending federal marijuana prohibition.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana legalization, syringe funding ban, overdose prevention.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 3, 2016.
Original Filing: 300825117.xml
Lobbying Issues
Opioid Overdose Reduction Act of 2014, issues related to overdose prevention.
Overdose Prevention Act, issues related to overdose prevention.
S. 524, Comprehensive Addiction Recovery Act
Issues related to federal syringe funding ban
S. 683, CARERS Act, issues related to medical marijuana.
H.R. 3537, the Synthetic Drug Control Act of 2015, issues related to DEA authority.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Sentencing Reform and Corrections Act, issues relating to drug sentencing.
FAIR Act, issues relating to civil asset forfeiture.
Issues related to ending federal marijuana prohibition.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana legalization, syringe funding ban, overdose prevention.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2016
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 3, 2016.
Original Filing: 300825112.xml
Lobbying Issues
Opioid Overdose Reduction Act of 2014, issues related to overdose prevention.
Overdose Prevention Act, issues related to overdose prevention.
S. 524, Comprehensive Addiction Recovery Act
Issues related to federal syringe funding ban
S. 683, CARERS Act, issues related to medical marijuana.
H.R. 3537, the Synthetic Drug Control Act of 2015, issues related to DEA authority.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Sentencing Reform and Corrections Act, issues relating to drug sentencing.
FAIR Act, issues relating to civil asset forfeiture.
Issues related to ending federal marijuana prohibition.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana legalization, syringe funding ban, overdose prevention.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2016
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 3, 2016.
Original Filing: 300825110.xml
Lobbying Issues
Opioid Overdose Reduction Act of 2014, issues related to overdose prevention.
Overdose Prevention Act, issues related to overdose prevention.
S. 524, Comprehensive Addiction Recovery Act
Issues related to federal syringe funding ban
S. 683, CARERS Act, issues related to medical marijuana.
H.R. 3537, the Synthetic Drug Control Act of 2015, issues related to DEA authority.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Smarter Sentencing Act, issues relating to drug sentencing.
Recidivism Reduction and Public Safety Act, issues relating to drug sentencing.
Sentencing Reform and Corrections Act, issues relating to drug sentencing.
FAIR Act, issues relating to civil asset forfeiture.
Issues related to ending federal marijuana prohibition.
Issues related to Higher Education Act drug conviction student loan ban.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana legalization, syringe funding ban, overdose prevention.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2015
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 28, 2016.
Original Filing: 300785548.xml
Lobbying Issues
Opioid Overdose Reduction Act of 2014, issues related to overdose prevention.
Overdose Prevention Act, issues related to overdose prevention.
S. 524, Comprehensive Addiction Recovery Act
Issues related to federal syringe funding ban
S. 683, CARERS Act, issues related to medical marijuana.
H.R. 3537, the Synthetic Drug Control Act of 2015, issues related to DEA authority.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Smarter Sentencing Act, issues relating to drug sentencing.
Recidivism Reduction and Public Safety Act, issues relating to drug sentencing.
Sentencing Reform and Corrections Act, issues relating to drug sentencing.
FAIR Act, issues relating to civil asset forfeiture.
Issues related to ending federal marijuana prohibition.
Issues related to Higher Education Act drug conviction student loan ban.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana legalization, syringe funding ban, overdose prevention.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2015
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 20, 2015.
Original Filing: 300763179.xml
Lobbying Issues
Opioid Overdose Reduction Act of 2014, issues related to overdose prevention.
Overdose Prevention Act, issues related to overdose prevention.
Issues related to federal syringe funding ban
S. 683, CARERS Act, issues related to medical marijuana.
H.R. 3537, the Synthetic Drug Control Act of 2015, issues related to DEA authority.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Smarter Sentencing Act, issues relating to drug sentencing.
Recidivism Reduction and Public Safety Act, issues relating to drug sentencing.
Sentencing Reform and Corrections Act, issues relating to drug sentencing.
FAIR Act, issues relating to civil asset forfeiture.
Issues related to ending federal marijuana prohibition.
Issues related to Higher Education Act drug conviction student loan ban.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana legalization, syringe funding ban, overdose prevention.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2015
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 21, 2015.
Original Filing: 300747185.xml
Lobbying Issues
Opioid Overdose Reduction Act of 2014, issues related to overdose prevention.
Overdose Prevention Act, issues related to overdose prevention.
Issues related to federal syringe funding ban
S. 683, CARERS Act, issues related to medical marijuana.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Smarter Sentencing Act, issues relating to drug sentencing.
Recidivism Reduction and Public Safety Act, issues relating to drug sentencing.
FAIR Act, issues relating to civil asset forfeiture.
Issues related to ending federal marijuana prohibition.
Issues related to Higher Education Act drug conviction student loan ban.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana legalization, syringe funding ban, overdose prevention.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2015
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 20, 2015.
Original Filing: 300723207.xml
Lobbying Issues
Opioid Overdose Reduction Act of 2014, issues related to overdose prevention.
Overdose Prevention Act, issues related to overdose prevention.
Issues related to federal syringe funding ban
S. 683, CARERS Act, issues related to medical marijuana.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Smarter Sentencing Act, issues relating to drug sentencing.
Recidivism Reduction and Public Safety Act, issues relating to drug sentencing.
FAIR Act, issues relating to civil asset forfeiture.
Issues related to ending federal marijuana prohibition.
Issues related to Higher Education Act drug conviction student loan ban.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to marijuana legalization, syringe funding ban, overdose prevention.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2014
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 20, 2015.
Original Filing: 300702422.xml
Lobbying Issues
S.2092, Opioid Overdose Reduction Act of 2014, issues related to overdose prevention.
S.2755, Overdose Prevention Act, issues related to overdose prevention.
Lobbying Issues
H.R.1523, Respect State Marijuana Laws Act of 2013, issues relating to legalizing marijuana.
S.1410, Smarter Sentencing Act of 2014, issues relating to sentencing reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R.83 - FY2015 Omnibus; Consolidated and Further Continuing Appropriations Act - issues related to D.C. and marijuana legalization
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R.83 - FY2015 Omnibus; Consolidated and Further Continuing Appropriations Act - issues related to medical marijuana and Justice Department.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2014
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 20, 2014.
Original Filing: 300685658.xml
Lobbying Issues
H2787, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2014, issues related to medical marijuana.
H.R.2786, Financial Services and General Government Appropriations Act, 2014, issues related to marijuana and D.C.
H.R.2786, Financial Services and General Government Appropriations Act, 2014, issues related to marijuana and banking.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S.2092, Opioid Overdose Reduction Act of 2014, issues related to overdose prevention.
S.2755, Overdose Prevention Act, issues related to overdose prevention.
Lobbying Issues
H.R.1523, Respect State Marijuana Laws Act of 2013, issues relating to legalizing marijuana.
S.1410, Smarter Sentencing Act of 2014, issues relating to sentencing reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2014
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Aug. 5, 2014.
Original Filing: 300671755.xml
Lobbying Issues
H2787, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2014, issues related to medical marijuana.
H2787, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2014, issues related to DEA funding.
S.1329, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2014, issues related to medical marijuana.
H.R.2786, Financial Services and General Government Appropriations Act, 2014, issues related to marijuana and banking. H.R.2786, Financial Services and General Government Appropriations Act, 2014, issues related to marijuana and D.C.
S. 1372, Department of State, Foreign Operations, and Related Programs Appropriations Act, Fiscal Year 2014, issues related to sentencing reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.4169, S.O.S. Act, issues relating to overdose prevention.
H.R.4288, Opioid Overdose Reduction Act of 2014, issues relating to overdose prevention.
S.2092, Opioid Overdose Reduction Act of 2014, issues relating to overdose prevention.
S.2755, A bill to prevent deaths occurring from drug overdoses, issues relating to overdose prevention
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1523, Respect State Marijuana Laws Act of 2013, issues relating to legalizing marijuana.
S.1410, Smarter Sentencing Act of 2014, issues relating to sentencing reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
1st Quarter, 2014
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on May 14, 2014.
Original Filing: 300651660.xml
Lobbying Issues
H.R. 499, Ending Federal Marijuana Prohibition Act of 2013, issues related to legalizing marijuana.
H.R. 1523, Respect State Marijuan Laws Act of 2013, issues relating to legalizing marijuana.
S. 1410, Smarter Sentencing Act of 2014, issues relating to drug sentencing.
S. 1675, Recidivism Reduction and Public Safety Act of 2014, issues relating to drug sentencing.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
S. 4169, S.O.S. Act, issues relating to overdose prevention.
Issues related to federal syringe funding ban..
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 22, 2014.
Original Filing: 300627188.xml
Lobbying Issues
S. 619, the Justice Safety Valve Act of 2013, issues related to mandatory minimum sentencing.
S. 1410, the Smarter Sentencing Act of 2013, issues related to mandatory minimum sentencing.
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 2642, the Federal Agriculture Reform and Risk Management Act of 2013, issues relating to SNAP and drug testing.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to drug overdoses.
Issues related to federal syringe funding ban.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 17, 2013.
Original Filing: 300596485.xml
Lobbying Issues
H.R. 499, Ending Federal Marijuana Prohibition Act of 2013, issues related to legalizing marijuana;
H.R. 964, Respect States' and Citizens' Rights Act of 2013, issues related to legalizing marijuana;
H.R. 1523, Respect STate Marijuana Laws Act of 2013, issues related to legalizing marijuana;
S. 619, the Justice Safety Valve Act of 2013, issues related to mandatory minimum sentencing;S. 744, Border Security, Economic Opportunity, and Immigration Modernization Act, issues related to immigation and drug policy;
S. 1410, Smarter Sentencing Act of 2014, issues related to mandatory minimum sentencing.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 2642, the Federal Agricutlre Reform and Risk Management Act of 2013, issues related to SNAP and drug testing
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to drug overdoses;
H.R. 689, States' Medical Marijuana Patient Protection Act, issues related to medical marijuana;
Issues related to federal syringe funding ban
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2013
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 22, 2013.
Original Filing: 300583507.xml
Lobbying Issues
H.R. 499, Ending Federal Marijuana Prohibition Act of 2013, issues related to legalizing marijuana;
H.R. 964, Respect States' and Citizens' Rights Act of 2013, issues related to legalizing marijuana;
H.R. 1523, Respect State Marijuana Laws Act of 2013, issues related to legalizing marijuana;
H.R. 446, National Criminal Justice Commission Act of 2013, issues related to over-incarceration;
S. 619, the Justice Safety Valve Act of 2013, issues related to mandatory minimum sentencing;
H.R. 2656, Public Safety Enhancement Act of 2013, issues relaed to BoP population and risk assessment;
H.R. 2652, Marijuana Businesses Access to Banking Act of 2013, issues related to marijuana and banking;
H.R. 784, States' Medical Marijuana Property Rights Protection Act, issues related to marijuana and asset forfeiture;
S. 744, Border Security, Economic Opportunity, and Immigration Modernization Act, issues related to immigration and drug policy.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 1947, the Federal Agriculture Reform and Risk Management Act (FARRM) of 2013, issues related to SNAP and drug testing, and issues related to legalizing hemp;
H.R. 6083, the Federal Agriculture Reform and Risk Management Act (FARRM), issues related to SNAP and drug testing, and issues related to legalizing hemp;
S.954, the Agriculture Reform, Food, and Jobs Act of 2013, issues related to legalizing hemp;
H.R. 525, the Industrial Hemp Farming Act of 2013, issues relatedd to legalizing hemp;
S. 359, the Industrial Hemp Farming Act of 2013, issues related to legalizing hemp;
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to drug overdoses;
H.R. 689, States' Medical Marijuana Patient Protection Act, issues related to medical marijuana;
H.R. 784, States' Medical Marijuana Property Rights Protection Act, issues related to medical marijuana;
H.R. 710, Truth in Trials Act, issues related to medical marijuana;
Issues related to federal syringe funding ban;
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2013
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 22, 2013.
Original Filing: 300560354.xml
Lobbying Issues
H.R. 499, Ending Federal Marijuana Prohibition Act of 2013, issues related to legalizing marijuana
H.R. 964, Respect States' and Citizens' Rights Act of 2013, issues related to legalizing marijuana
H.R. 1523, Respect State Marijuana Laws Act of 2013, issues related to legalizing marijuana
H.R. 446, National Criminal Justice Commission Act of 2013, issues related to over-incarcerationS. 619, the Justice Safety Valve Act of 2013, issues related to mandatory minimum sentencing
Issues relaed to BoP population and possible risk assessment legislation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to drug overdoses
H.R. 689, States' Medical Marijuana Patient Protection Act, issues related to medical marijuana
H.R. 784, States' Medical Marijuana Property Rights Protection Act, issues related to medical marijuana
H.R. 710, Truth in Trials Act, issues related to medical marijuana
Issues related to federal syringe funding ban
Issues related to medical marijuana and veterans
Agencies Lobbied
U.S. House of Representatives Substance Abuse & Mental Health Services Administration (SAMHSA) U.S. Senate
Lobbying Issues
S. 359, Industiral Hemp Farming Act of 2013, issues related to legalizing hemp
H.R. 525, Industrial Hemp Farming Act of 2013, issues related to legalzing hemp
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2012
DRUG POLICY ALLIANCE amended a lobbying report for in-house lobbying in Q42012 on May 27, 2014
Original Filing: 300652193.xml
Lobbying Issues
S. 306, National Criminal Justice Commission Act of 2011, issues related to over-incarceration.
H.R. 2306, Ending Federal Marijuana Prohibition Act of 2011, issues related to legalizing marijuana.
Issues related to appopriations for Byrne-Jag grants, COPS, drug courts, Second Chance Act funding
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 6311, the Stop Overdose Stat Act, issues related to overdose and naloxone
H.R. 1983, States' Medical Marijuana Patient Protection Act, issues related to medical marijuana
H.R. 1984, Small Business Banking IMprovement Act of 2011, issues related to medical marijuana
H.R. 1985, Small Business Tax Equity Act of 2011, issues related to medical marijuana
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Feb. 20, 2013.
Original Filing: 300545629.xml
Lobbying Issues
S. 306, National Criminal Justice Commission Act of 2011, issues related to over-incarceration
H.R. 2306, Ending Federal Marijuana Prohibition Act of 2011, issues related to legalizing marijuana
Issues related to appropriations for Byrne-Jag grants, COPS, drug courts, Second Chance Act funding
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 6311, the Stop Overdose State Act, issues related to overdose and naloxone
H.R. 1983, States' Medical Marijuana Patient Protection Act, issues related to medical marijuana
H.R. 1984, Small Business Banking Improvement Act of 2011, issues related to medical marijuana
H.R. 1985, Small Business Tax Equity Act of 2011, issues related to medical marijuana
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 22, 2012.
Original Filing: 300516442.xml
Lobbying Issues
S. 306, National Criminal Justice Commission Act of 2011, issues related to over-incarceration.
H.R. 2306, Ending Federal Marijuana Prohibition Act of 2011, issues relating to legalizing marijuana.
Issues related to federal prison spending.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
S. 3240, Agriculture Reform, Food, and Jobs Act of 2012, issues related to drug offenders and TANF.
H.R. 6083, Federal Agriculture REform and Risk Management of 2012, issues related to drug offenders and TANF.
S. 3602, Food Stamp Restoration Act of 2012, issues related to drug offenders and TANF.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1983, States' Medical Marijuana Patient Protection Act, issues related to medical marijuana.
H.R. 1984, Small Business Banking Improvement Act of 2011, issues related to medical marijuana.
H.R. 1985, Small Business Tax Equity Act of 2011, issues related to medical marijuana.
H.R. 6311, S.O.S. Act, issues related to overdose prevention.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 19, 2012.
Original Filing: 300490977.xml
Lobbying Issues
S. 306, National Criminal Justice Commission Act of 2011, issues related to over-incarceration
H.R. 1254, Synthetic Drug Control Act of 2011, issues relating to Spice, "bath salts", and the scheduling system
H.R. 2306, Ending Federal Marijuana Prohibition Act of 2011, issues relating to legalizing marijuana.
H.AMDT.1084 to H.R.5326, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2013, issues related to medical marijuana.
S. 2323, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2013, issues related to medical marijuana.
H.R. 6020, Financial Services and General Government Appropriations Act, 2013, issues related to medical marijuana.
Issues related to Byrne Grant funding.
Issues related to federal prison spending.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to overdose and naloxone.
H.R. 1983, States' Medical Marijuana Patient Protection Act, issues related to medical marijuana.
H.R. 1984, Small Business Banking Improvement Act of 2011, issues related to medcial marijuana.
H.R. 1985, Small Business Tax Equity Act of 2011, issues related to medical marijuanaIssues related to federal syringe funding ban.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 18, 2012.
Original Filing: 300463692.xml
Lobbying Issues
S. 306, National Criminal Justice Commission Act of 2011, issues related to over-incarceration.
H.R. 313, Drug Trafficking Safe Harbor Elimination Act of 2011, issues related to drug conspiracy law
S. 1672, Drug Trafficking Safe Harbor Elimination Act of 2011, issues related to drug conspiracy law
H.R. 1254, Synthetic Drug Control Act of 2011, issues related to Spice, "bath salts", and the scheduling systemH.R. 2306, Ending Federal Marijuana Prohibition Act of 2011, issues relating to legalizing marijuana.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues related to overdose and naloxone.
H.R. 1983, States' Medical Marijuana Patient Protection Act, issues related to medical marijuana.
H.R. 1985, Small Business Tax Equity Act of 2011, issues related to medical marijuana.
H.R. 1984, Small Business Banking Improvement Act of 2011, issues related to medical marijuana Access to Substance Abuse Treatment Act of 2012
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 20, 2012.
Original Filing: 300448126.xml
Lobbying Issues
S. 306, National Criminal Justice Act of 2011, issues related to over-incarceration
H.R. 313, Drug Trafficking Safe Harbor Elimination Act of 2011, issues related to drug conspiracy law
S. 1672, Drug Trafficking Safe Harbor Elimination Act of 2011, issues related to drug conspiracy law
H.R. 1254, Synthetic Drug Control Act of 2011, issues related to Spice, "Bath Salts", and the scheduling systemH.R. 2306, Ending Federal Marijuana Prohibition Act of 2011, issues relating to legalizing marijuana.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H2055, Consolidated Appropriatons Act, issues relating to DC syringe ban.
H2055, Consolidated Appropriations Act, issues relating to federal syringe ban
H2055, Consolidated Appropriations Act, issues related to National Youth Anti-Drug Media Campaign
H.R. 1983, States' Medical Marijuana Patient Protection Act, issues related to medical marijuanaH.R. 1985, Small Business Tax Equity Act of 2011, issues related to medical marijuana
H.R. 1984, Small Business Banknig Improvement Act of 2011, issues related to medical marijuana
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3765, Temporary Payroll Tax Cut Continuation Act of 2011, issues relating to drug testing of unemployment benefits applicants
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 20, 2011.
Original Filing: 300424378.xml
Lobbying Issues
S. 306, National Criminal Justice Act of 2011, issues related to over-incarceration
H.R. 313, Drug Trafficking Safe Harbor Elimination Act of 2011, issues related to drug conspiracy law
H.R. 1254, Synthetic Drug Control Act of 2011, issues related to Spice, "Bath Salts", and the scheduling system
FY 2012 Commerce, Justice, Science Appropriations bill, issues related to funding for Byrne/JAG and COPS programsH.R. 2306, Ending Federal Marijuana Prohibition Act of 2011, issues relating to legalizing marijuana
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
FY 2012 Financial Services and General Government Appropriations bill, issues related to DC syringe ban
H.R. 1983, States' Medical Marijuana Patient Protection Act, issues related to medical marijuana
H.R. 1985, Small Business Tax Equity Act of 2011, issues related to medical marijuana
H.R. 1984, Small Business Banknig Improvement Act of 2011, issues related to medical marijuana
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 20, 2011.
Original Filing: 300400258.xml
Lobbying Issues
S. 306, National Criminal Justice Commission Act of 2011, issues related to over-incarceration
H.R. 2242, Fairness in Cocaine Sentencing Act of 2011, issues related to crack/powder cocaine sentencing disparity
H.R. 2316 , Fair Sentencing Claification Act of 2011, issues related to crack/powder cocaine sentencing disparity
H.R. 2303, Major Drug Trafficking Prosecution Act of 2011, issues related to mandatory minimum sentencingFY 2012 Commerce, Justice, Science Appropriations bill, issues related to funding for Byrne/JAG and COPS programs
H.R. 2306, Ending Federam Marijuana Prohibition Act of 2011, issues relating to legalizing marijuana
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
FY 2012 Financial Services and General Government Appropriations bill, issues related to DC syringe ban
H.R. 1983, States' Medical Marijuana Protection Act, issues related to medical marijuana
H.R. 1985, Small Business Tax Equity Act of 2011, issues related to medical marijuana
H.R. 1984, Small Business Banking Improvement Act of 2011 , issues related to medical marijuana
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 8, 2011.
Original Filing: 300361168.xml
Lobbying Issues
S. 306, National Criminal Justice Commission Act of 2011, issues related to over-incarceration
H.R. 313, Drug Trafficking Safe Harbor Elimination Act of 2011, issues related to drug conspiracy laws
S. 409, Combating Dangerous Synthetic Stimulants Act of 2011, issues related to drug scheduling
S. 605, Dangerous Synthetic Drug Control Act of 2011, issues related to drug schedulingS. 513, Saving Kids From Dangerous Drugs Act of 2011, issues related to medical marijuana
H.R. 82, Drug Court Reauthorization Act, issues related to drug courts
H.R. 1, Full-Year Continuing Appropriations Act of 2011, issues related to funding for Byrne/JAG and COPS programs
H.R. 1, Full-Year Continuing Appropriations Act of 2011, issues related to civil asset forfeiture
Issues relating to marijuana legalization and regulation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 1, Full-Year Continuing Appropriations Act of 2011, issues related to federal syringe ban
H.R. 1, Full-Year Continuing Appropriations Act of 2011, issues related to funding to National Youth Anti-Drug Media Campaign
Issues related to overdose prevention
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1, Full-Year Continuing Appropriations Act of 2011, issues relating to funding for Safe and Drug Free Schools program
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 20, 2011.
Original Filing: 300355743.xml
Lobbying Issues
H.R. 2855, Drug Overdose Reduction Act, issues relating to reducing drug overdoses
Issues relating to Appropriations for the National Youth Anti-Drug Media Campaign
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 714, National Criminal Justice Commission Act of 2009, issues relating to over-incarceration
Issues relating to the reauthorization of the Office of National Drug Control Policy
S. 1516, Democracy Restoration Act of 2009, issues related to voting rights
H.R. 3335, Democracy Restoration Act of 2009, issues related to voting rightsH.R. 6548, Fair Sentencing Clarification Act of 2010, issues relating to crack/powder cocaine sentencing disparity
H.R. 5231, Drug Trafficking Safe Harbor Elimination Act of 2010, issues related to drug conspiracy laws.
H.R. 5748, End Racial Profiling Act of 2010, issues related to racial profiling.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 3134, Western Hemisphere Drug Policy Commission Act of 2009, issues relating to interdiction and eradication
S. 4011, Western Hemisphere Drug Policy Commission Act of 2009, issues relating to interdiction and eradication
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 20, 2010.
Original Filing: 300325123.xml
Lobbying Issues
H.R. 2855, Drug Overdose Reduction Act, issues relating to reducing drug overdoses
H.R. 5678, Universal Access to Methamphetamine Treatment Act of 2010, issues relating to treatment for methamphetamine misuse.
Issues relating to Appropriations for the National Youth Anti-Drug Media Campaign
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3245, Fairness in Cocaine Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity
S. 714, National Criminal Justice Commission Act of 2009, issues relating to over-incarceration
S. 258, Saving Kids from Dangerous Drugs Act of 2010, issues relating to federal sentencing
Issues relating to the reauthorization of the Office of National Drug Control Policy
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2010
DRUG POLICY ALLIANCE amended a lobbying report for in-house lobbying in Q22010 on July 30, 2010
Original Filing: 300305799.xml
Lobbying Issues
H.R. 2855, Drug Overdose Reduction Act, issues relating to reducing drug overdoses
H.R. 5678, Universal Access to Methamphetamine Treatment Act of 2010, issues relating to treatment for methamphetamine misuse
Issues relating to Appropriations for the National Youth Anti-Drug Media Campaign
Agencies Lobbied
U.S. House of Representatives Office of Natl Drug Control Policy (NDCP)
Lobbying Issues
H.R. 3245, Fairness in Cocaine Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity
S. 1789, Fair Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity
S. 714, National Criminal Justice Commission Act of 2009, issues relating to over-incarceration
Issues relating to the reauthorization of the Office of National Drug Control Policy
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2010
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 20, 2010.
Original Filing: 300300406.xml
Lobbying Issues
H.R. 2855, Drug Overdose Reduction Act, issues relating to reducing drug overdoses
H.R. 5678, Universal Access to Methamphetamine Treatment Act of 2010, issues relating to treatment for methamphetamine misuse
Issues relating to Appropriations for the National Youth Anti-Drug Media Campaign
Agencies Lobbied
U.S. House of Representatives Office of Natl Drug Control Policy (NDCP)
Lobbying Issues
H.R. 3245, Fairness in Cocaine Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity
S. 1789, Fair Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity
S. 714, National Criminal Justice Commission Act of 2009, issues relating to over-incarceration
Issues relating to the reauthorization of the Office of National Drug Control Policy
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Type of Issue
Law Enforcement/Crime/Criminal Justice
1st Quarter, 2010
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 19, 2010.
Original Filing: 300265133.xml
Lobbying Issues
H.R. 2855, Drug Overdose Reduction Act, issues relating to reducing drug overdoses.
Issues relating to drug treatment for methamphetamine abuse.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3245, Fairness in Cocaine Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity.
S. 1789, Fair Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity
S. 714, National Criminal Justice Commission Act of 2009, issues relating to over-incarceration
Issues relating to reauthorization of Office of Natioanl Drug Control Policy
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 4872, Health Care and Education Reconciliation Act of 2010, issues relating to prohibition on students convicted of drug law offenses from receiving student loans and other education assistance.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 20, 2010.
Original Filing: 300247157.xml
Lobbying Issues
H.R. 3288, 2010 Consolidated Appropriations Act, issues relating to federal syringe ban.
H.R. 2855, Drug Overdose Reduction Act, issues relating to reducing drug overdoses.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3245, Fairness in Cocaine Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity.
S. 714, National Criminal Justice Commission Act of 2009, issues relating to over-incarceration.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2009
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 20, 2009.
Original Filing: 300214775.xml
Lobbying Issues
FY10 Labor-HHS-Education spending bill, issues relating to federal syringe ban.
H.R. 2855, Drug Overdose Reduction Act, issues relating to reducing drug overdoses.
H.R. 2943, Personal Use of Marijuana by Responsible Adults Act of 2009, issues relating to reduced penalties for marijuana possession.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3245, Fairness in Cocaine Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity.
S. 714, National Criminal Justice Commission Act of 2009, issues relating to over-incarceration.
H.R. 1412, Justice Integrity Act of 2009, issues relating to racial disparities in the criminal justice system.
S. 495, Justice Integrity Act of 2009, issues relating to racial disparities in the criminal justice system. Issues relating to taxing and regulating marijuana like alcohol.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 3221, Student Aid and Fiscal Responsibility Act of 2009, issues relating to prohibition on students convicted of drug law offenses from receiving student loans and other education assistance.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 20, 2009.
Original Filing: 300192977.xml
Lobbying Issues
H.R. 179, Community AIDS and Hepatitis Prevention Act, issues relating to federal syringe ban.
FY10 Labor-HHS-Education spending bill (no bill number), issues relating to federal syringe ban.
H.R. 2855, Drug Overdose Reduction Act, issues relating to reducing drug overdoses.
Issues relating to drug treatment for methamphetamine abuse.H.R. 2943, Personal Use of Marijuana by Responsible Adults Act of 2009, issues relating to reduced penalties for marijuana possession.
H.R. 3170, Financial Services and General Government Appropriations Act, 2010, issues relating to National Youth Anti-Drug Media Campaign.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 265, Drug Sentencing Reform and Cocaine Kingpin Trafficking Act of 2009, issues relating to the crack/powder sentencing disparity.
H.R. 1459, Fairness in Cocaine Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity.
H.R. 2178, Crack-Cocaine Equitable Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity.S. 714, National Criminal Justice Commission Act of 2009, issues relating to over-incarceration.
Issues relating to Mexico / U.S. border violence.
H.R. 1412, Justice Integrity Act of 2009, issues relating to racial disparities in the criminal justice system.
S. 495, Justice Integrity Act of 2009, issues relating to racial disparities in the criminal justice system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 3170, Financial Services and General Government Appropriations Act, 2010, issues relating to prohibition on medical marijuana in Washington, DC.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on April 20, 2009.
Original Filing: 300161698.xml
Lobbying Issues
H.R. 179, Community AIDS and Hepatitis Prevention Act, issues relating to federal syringe ban.
Issues relating to drug overdoses.
Issues relating to drug treatment for methamphetamine abuse.
Issues relating to TRICARE and Department of Defense health insurance coverage for drug treatment.Issues relating to student drug testing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 265, Drug Sentencing Reform and Cocaine Kingpin Trafficking Act of 2009, issues relating to the crack/powder sentencing disparity.
H.R. 1459, Fairness in Cocaine Sentencing Act of 2009, issues relating to the crack/powder sentencing disparity.
S. 714, National Criminal Justice Commission Act of 2009, issues relating to over-incarceration.Issues relating to restoring the right to vote to people with felony convictions.
Issues relating to marijuana law reform.
Issues relating to crack/powder sentencing disparity.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Issues relating to reauthorization of Office of National Drug Control Policy (ONDCP).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Jan. 15, 2009.
Original Filing: 300120807.xml
Lobbying Issues
H.R. 5842, Medical Marijuana Patient Protection Act
H.R. 6680, Community Aids and Hepatitis Prevention Act, issues relating to federal syringe ban.
Issues relating to drug overdoses.
Issues relating to drug treatment for methamphetamine abuse.Issues relating to student drug testing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1383, Drug Sentencing Reform Act of 2007, issues relating to the crack/powder sentencing disparity.
S. 1711, Drug Sentencing Reform and Cocaine Kingpin Act, issues relating to the crack/powder sentencing disparity.
Issues relating to the Byrne Justice Assistance Grant Program and H.R. 3546, To authroize the Edward Byrne Memorial Justice
Assistance Grant Program at fiscal year 2006 levels through 2012.H.R. 4545, Drug Sentencing Reform and Cocaine Kingpin Trafficking Act of 2007, issues relating to the crack/powder
sentencing disparity.
S. 1685, Fairness in Drug Sentencing Act of 2007, issues relating to the crack/powder sentencing disparity.
H.R. 5843, Act to Remove Federal Penalties for the Personal Use of Marijuana by Responsible Adults.
Issues relating to restoring the right to vote to people with felony convictions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
3rd Quarter, 2008
In Q3, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on Oct. 16, 2008.
Original Filing: 300095564.xml
Lobbying Issues
Issues relating to the Byrne Justice Assistance Grant Program and H.R. 3546, To authorize the Edward Byrne Memorial Justice
Assistance Grant Program at fiscal year 2006 levels through 2012.
S. 1383, Drug Sentencing Reform Act of 2007, issues relating to the crack/powder sentencing disparity.
S. 1711, Drug Sentencing Reform and Cocaine Kingpin Act, issues relating to the crack/powder sentencing disparity.H.R. 4545, Drug Sentencing Reform and Cocaine Kingpin Trafficking Act of 2007, issues relating to the crack/powder
sentencing disparity.
S. 1685, Fairness in Drug Sentencing Act of 2007, issues relating to the crack/powder sentencing disparity.
S. 1211, Saving Kids from Dangerous Drugs Act of 2007, issues relating to medical marijuana.
H.R. 5843, Act to Remove Federal Penalties for the Personal Use of Marijuana by Responsible Adults.
Issues relating to restoring the right to vote.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
H.R. 5842, Medical Marijuana Patient Protection Act.
H.R. 6680, Community AIDS and Hepatitis Prevention Act, issues relating to federal syringe ban.
Issues relating to drug overdoses.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, DRUG POLICY ALLIANCE had in-house lobbyists. The report was filed on July 21, 2008.
Original Filing: 300082419.xml
Lobbying Issues
S. 2767, To provide for judicial discretion regarding suspensions of student eligibility under section 484(r) of the Higher Education Act of 1965.
Issues relating to the Higher Education Act Aid Elimination.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 5842, Medical Marijuana Patient Protection Act.
HR 5843, Act to Remove Federal Penalties for the Personal Use of Marijuana by Responsible Adults.
Issues relating to the federal syringe ban.
Issues relating to health care coverage for methadone and buprenorphine treatments.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 3546, To authorize the Edward Byrne Memorial Justice Assistance Grant Program at fiscal year 2006 levels through 2012.
S 1383, Drug Sentencing Reform Act of 2007, issues relating to the crack/powder sentencing disparity.
Issues relating to restoring the right to vote.
S 1711, Drug Sentencing Reform and Cocaine Kingpin Trafficking Act of 2007, issues relating to the crack/powder sentencing disparity.
HR 4545, Drug Sentencing Reform and Cocaine Kingpin Trafficking Act of 2007, issues relating to the crack/powder sentencing disparity.
S 1685, Fairness in Drug Sentencing Act of 2007, issues relating to the crack/powder sentencing disparity.
HR 6021, To prohibit the purchase or lease of housing acquired using Federal loan or grant funds appropriated for the purchase and rehabilitation of foreclosed housing under the Neighborhood Stabilization Act of 2008 by any individual convicted under Federal or State law of a drug-dealing offense, a sex offense, or mortgage fraud.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
1st Quarter, 2008
DRUG POLICY ALLIANCE amended a lobbying report for in-house lobbying in Q12008 on July 21, 2008
Original Filing: 300082406.xml
Lobbying Issues
Issues relating to the Higher Education Act Aid Elimination.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues and legislative policies relating to medical marijuana.
Issues relating to the federal syringe ban.
Issues relating to overdose prevention.
Issues relating to the treatment of methamphetamine addicts.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S 1383, Drug Sentencing Reform Act of 2007, provisions relating to the crack/powder sentencing disparity.
S 1711, Drug Sentencing Reform and Cocaine Kingpin Trafficking Act of 2007, provisions relating to the crack/powder sentencing disparity.
HR 4545, Drug Sentencing Reform and Cocaine Kingpin Trafficking Act of 2007, provisions relating to the crack/powder sentencing disparity.
S. 1685, Fairness in Drug Sentencing Act of 2007, provisions relating to the crack/powder sentencing disparity.
Issues relating to treatment of methamphetamine addicts.
Issues relating to medical marijuana.
Issues relating to the federal syringe ban.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
1st Quarter, 2008
DRUG POLICY ALLIANCE amended a lobbying report for in-house lobbying in Q12008 on May 7, 2008
Original Filing: 300058206.xml
Lobbying Issues
Crack/powder cocaine sentencing reform, HEA Aid Elimination Penalty, DC syringe ban, federal syringe ban
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Civil Rights/Civil Liberties
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate